Rhodamine 123 has been shown to be a substrate for P-glycoprotein in multidrug resistant cells, In the present investigation the disposition of rhodamine 123 was studied in the isolated perfused rat kidney, After exposing the kidneys to perfusate concentrations ranging from 10 to 1000 n g/m l, the renal clearance was 4-1 times the clearance by glomerular filtration, respectively, indicating active and saturable secretion of rhodamine 123. The rate-limiting step in secretion was found to be membrane passage from cell to tubular lumen. Suprisingly, renal clearance was not influenced by the P-glycoprotein inhibitors cyclosporin A or digoxin. However, pretreatment o f the kidneys with verapamil and quinidine (inhibitors of both P-glycoprotein and organic cation transport) or cimetidine (organic cation transport inhibitor) resulted in a significantly reduced rhodamine 123 clearance, indicating that the renal organic cation carrier may be involved in active secretion. Rhodamine 123 accumulated extensively in the isolated perfused rat kidney; tissue concentrations o f 2 7 0 -3 6 0 times the perfusate concentration were determined. Similar accumulation ratios at different perfusate concentrations were found, suggesting that the compound enters the tubular cells by (facilitated) diffusion. In conclusion, rhodamine 123 accumulated extensively in the isolated perfused rat kidney and active renal secretion appears to be pi*eferentially mediated by the organic cation carrier and not by P-glycoprotein.
Introduction
Resistance to various chemotherapeutic drugs is a phe nomenon often observed in patients and cell cultures. Drug resistance associated with the overexpression of the mul tidrug resistance-1 gene, which encodes the P-glycoprotein or multidrug transport protein, is characterized by a re duced intracellular drug accumulation and increased cellu lar drug efflux. P-glycoprotein is an ATP-dependent inte gral membrane protein, which is not only expressed in resistant tumor cells, but also in normal tissues such as liver, intestine, adrenal gland, placenta and kidney. The physiological function of P-glycoprotein is not clear, but its apical distribution in secretory epithelia and role in drug efflux suggest that P-glycoprotein may function in the excretion of endogenous compounds and naturally occur ring toxins (Ford and Hait, 1990; Thibaut et al., 1987; Gottesman and Pastan, 1993; Leveille-Webster and Arias, 1995; Al-Awqati, 1995) . Physiological substrates for Pglycoprotein are cortisol, dexamethasone and aldosterone, whereas progesterone is a potent inhibitor of P-glyco protein-mediated transport (Ichikawa-Haraguchi et al., 1993; Ueda et al., 1992) . Other substrates for P-glyco protein are anthracylines, vinca alkaloids, epipodophyllotoxins, taxol, actinomycin D (Ford and Hait, 1990) . Fur thermore, the widely used cardiac glycoside, digoxin, is actively secreted into urine by P-glycoprotein in the kidney (De Lannoy et al., 1992; Hori et a l, 1993) ,
The ability to excrete these substrates can be reduced by treatment with chemosensitizers, compounds that reverse or antagonize multidrug resistance. The group of inhibitors consists of a wide variety of structurally unrelated drugs, including calcium channel blockers, hormones and steroids, hydrophobic peptides, cyclosporins, calmodulin antago nists, and miscellaneous hydrophobic cationic drugs, It is suggested that the interaction between substrates and in hibitors is related to a common binding site on P-glyco protein.
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PII 8 0 0 1 4 -2 9 9 9 (9 6 )0 0 9 5 7 -0 316 R. Masereeuw et at. / European Journal o f Pharmacology 321 (1997) [315] [316] [317] [318] [319] [320] [321] [322] [323] also be due to competition for transport. ATP binding is not blocked by any of the reversal agents, indicating separate ATP and drug binding sites on P-glycoprotein (Ford and Hait, 1990; Gottesman and Pastan, 1993; Leveille-Webster and Arias, 1995) .
The proximal tubule of the kidney is the most important site in active renal drug elimination, and proximal tubular cells contain separate systems for organic anions and cations. The active step in the secretion of organic anions is located at the basolateral membrane, and that of organic cations at the luminal membrane (Pritchard and Miller, 1993) . In addition, P-glycoprotein is also present at the luminal membrane (Lieberman et al., 1989) . Several hy drophobic amines known to interact with the classical organic cation transport system, for example verapamil, quinine, quinidine, and quinacrine, inhibit P-glycoproteinmediated transport. For this reason P-glycoprotein was suggested to be an unidentified component of the renal organic cation carrier, however, photoaffinity labeling studies implied that separate carrier systems exist (Holohan et al., 1992) . More recently, it was shown in a functional expression system in Xenopits laevis oocytes, that P-glycoprotein and the organic cation earner are in deed different transport proteins (Nelson et al., 1995) .
In the present investigation the transport mechanisms of rhodamine 123 and the interaction with various cationic drugs were studied in the isolated perfused rat kidney. This in vitro technique has been shown useful for the investiga tion of renal organic anionic and cationic drug excretion (Cox et al., 1990; Boom et aL, 1994) . Previous investiga tions in various carcinoma cells showed that the mitochon drial dye with anticarcinoma activity, rhodamine 123 , is effectively pumped out of these cells via P-glycoprotein (Neyfakh et al., 1989; Lee et al., 1994; Denis-Gay et al., 1995) . More recently, rhodamine 123 resistance was found to be related to the expression of the mdrl gene in a monkey kidney epithelial cell line, although direct evidence that rhodamine 123 is transported by P-glycoprotein in this cell line was not obtained (Brouty-Boye et a l, 1995) . Rhodamine 123 is not in use as a drug, but because of its excellent fluorescent properties and transport characteristics it is a potential model com pound for studying P-glycoprotein-mediated transport in the kidney and other organs. Aim of our study was to investigate the role of P-glycoprotein as a drug transport system in the isolated perfused rat kidney.
Materials and methods

Methods
2JJ. Kidney isolation and perfusion
The isolation and perfusion of the rat kidney and stabil ity of the perfused kidney system were described in detail previously (Cox et al., 1990) . Briefly, male Wistar-Hannover rats (225-275 g) were anesthetized intraperitoneally with pentobarbital (6 mg/ 100 g) and furosemide was injected intraperitoneally (1 mg/ 100 g) to prevent deterio ration of the distal nephron. Heparin (125 I.U ./100 g) was injected via the femoral vein. The ureter of the right kidney was cannulated and the renal artery via the mesen teric artery without interruption of the blood flow. The kidney was then excised and placed in a fluid bath with a constant temperature of 37.5°C. The perfusion fluid had the following composition (mM, except where indicated otherwise): NaCl 114.0, KC1 5.2, CaCl2 1.8, MgCU 1.0, N aH C 03 22.5, N a2H P 0 4 0.84, K H 2P 0 4 0.28, glucose 5.0, urea 4.0, pluronic F108 25.0 g /I, glutathione 0.33, inositol 0.083, cysteine 0.50, glycine 2.3, Na-pyruvate 2.0, Na-acetate 1.22, Na-propionate 0.21, inosine 1.0, alanine 5.0, glutamine 0.11, L-glutamic acid 2.0, a-ketoglutarate 1.15, ascorbic acid 0.01, Na-lactate 1.0, choline chloride 1.0 mg/1, insulin 4 I.U ./l, aldosterone 2.0 fig/1 , lysinevasopressin 0.01 I.U ./l, and angiotensin II 15.0 ng/1. To this solution 1.0% Synthamin 14, a mixture of 15 amino acids, was added. Pluronic F-108 was used as oncotic agent in the albumin-free perfusion fluid. For the determi nation of glomerular filtration rate, inulin was added to the perfusion fluid (100 |j,g/m l).
Clearance experiments
In our perfused kidney preparation, perfusion medium was recirculated at a constant flow rate with a perfusate pressure of approximately 90 mmHg. During the first 5 min of perfusion, the venous effluent was discarded and after this period the perfusion fluid was recirculated and the kidney was allowed to stabilize for 30 min. Then the experiment was started with a 30 min baseline period, after which rhodamine 123 was administered. During the base line period the perfusate volume was 500 ml from which a sample of 5 ml was drawn. After the baseline period, the experimental fluid was connected to the kidney, with a total volume of 150 ml in which rhodamine 123 was already dissolved. The experimental period was 120 min. Doses added to the perfused kidneys were 0 (time con trols), 1.5, 15, 52,5 and 150 jig of rhodamine 123, result ing in initial perfusate concentrations of 0, 10, 100, 350 and 1000 ng/m l. The influence on rhodamine 123 clear ance of the following compounds were studied: cy closporin A and digoxin (P-glycoprotein-inhibitors), vera pamil and quinidine (organic cation transport and P-glyco protein inhibitors), and cimetidine (organic cation transport inhibitor). All inhibitory agents were added to the isolated perfused rat kidney at the start of the baseline period, and remained in perfusion fluid during the experimental period. Urine samples were collected during control and experi mental periods over 10 min intervals. Perfusate samples (500 |jl1) were drawn at the midpoint of each urine collec tion interval. Two additional perfusate samples were taken, one at the beginning of the experimental period ( / = 0), and one at the end of the experiment. At the end of the experiment the kidney was removed from the system, blotted, weighed, and frozen until analysis. Urine and perfusate samples were stored at -20°C until analysis. Perfusion fluid during experimental period, and perfusion an d urine samples were protected from light.
, 1 3 . Preload experiments
Kidneys were isolated and perfused in a similar way as described above for the clearance experiments, except for th e experimental period. The 30 min baseline period was followed by a 60 min preload period, in which 150 jxg rhodamine 123 was added to perfusion medium (150 ml). Subsequently an efflux period was studied for 90 min, at w hich kidneys were perfused with clean perfusion fluid (1000 ml) without recirculation. After 40 min of efflux a urinary flow change from 60 to 16 jxl/min was induced b y changing the perfusate flow rate from 16 to 11 ml/min. W henever verapamil was used to inhibit rhodamine 123 transport, this agent was added to perfusion fluid at the start of the baseline period and remained in perfusion fluid during the preload and efflux period. Urine samples were collected during all periods over 10 min intervals. Per fusate samples (400 jjl! ) were drawn at the beginning and after 5, 15, 35, 55 and 60 min of the preload period. D uring the single-pass efflux period, samples of 600 p,l w ere drawn from the perfusion fluid every 5 min, and one at the end of the efflux period. Perfusate and urine sam ples, and kidneys were handled as described for the clear ance experiments,
Analysis
Urine and perfusate samples were analyzed for glucose and various electrolytes as described previously (Cox et al., 1990) . Inulin was determined according to a previously published method (Heyrovski, 1956) . The concentration of rhodamine 123 in perfusate, urine and kidney samples was determined by means of fluorescence spectrophotometry. To this end, an aliquot of 2-200 |xl of the perfusate sample or 0.5-20 jxl of the urine samples was taken and adjusted to 600 jxl with analysis buffer (0.01 M KH2P 0 4, pH 2.6), and fluorescence was measured using a Perkin Elmer LS50 luminescence spectrophotometer (Perkin Elmer, Beaconsfield, Buckinghamshire, UK). The excita tion wavelength was set to 501 nm, the emission wave length to 531 nm and for both wavelengths a slit width of 5 nm was used. Concentrations were calculated by compar ing fluorescence intensity (in photomultiplier units) with a calibration curve of spiked samples of blank perfusion fluid with different concentrations of rhodamine 123. The concentration of rhodamine 123 in kidney tissue was deter mined similarly. The kidneys were homogenized in 5 ml distilled water with a Polytron homogenizer (Braun Melsungen, Germany) on setting 10 for 2 times 60 s. Subse quently, to 50 (j l I of the kidney homogenate 250 (j l I acetonitrile was added, vortexed and centrifuged for 10 min at 2000 X g. Of the supernatant, an aliquot of 200 jjlI was added to ice-cold glass tubes and evaporated until dryness. The residue was dissolved in 600 jutl analysis buffer, either undiluted or 10-50 times diluted (dependent on the expected concentration), and fluorescence intensi ties of triplicate samples was measured and averaged. Concentrations were calculated by comparing fluorescence intensity with a calibration curve of spiked samples of blank kidney homogenates with various concentrations of i rhodamine 123. Linear calibration curves were obtained in all cases (r2> 0.998). Rhodamine 123 did not bind to pluronic F-108. This was checked by means of ultrafiltra tion using YM-10 membranes with a molecular weight cut-off of 10000 in the MPS-1 micropartition system (Amicon, Grace B.V., Dronten, Netherlands),
Data analysis
All data are expressed as means ± S,D. Statistical dif ferences between means were determined with one-way analysis of variance followed by the least significant dif ference test for comparison of multiple means. Differences were considered significant if P < 0.05. The concentration of rhodamine 123 in kidney tissue (CT) was expressed as the amount of drug per weight of tissue.
2,2. Materials
Sodium pentobarbital was obtained from Apharmo (Arnhem, Netherlands). Heparin, aldosterone and inulin were from Organon (Oss, Netherlands). Rhodamine 123 was purchased from ICN (Costa Mesa, CA, USA), lysinevasopressin from Sandoz Pharma (Basel, Switzerland), angiotensin II from Beckman (Palo Alto, CA, USA) and Synthamin 14 was from Travenol (Thetford, Norfolk, UK). Cyclosporin A was kindly provided by Sandoz Pharma (Basel, Switzerland) and Pluronic F-108 was obtained from BASF (Arnhem, Netherlands). All other chemicals were of analytical grade and obtained either from Sigma (St. Louis, MO, USA) or Merck AG (Darmstadt, Ger many). A stock solution of cyclosporin A was prepared in DMSO (20 m g/m l).
Results
Effect on kidney function
The mean values for the functional parameters of base line period ( -3 0 -0 min) of all isolated perfused rat kidney experiments are presented in Table 1 . The control values (first data column) represent mean values of all experiments in which rhodamine 123 was added solely to the perfused kidney system. The other columns show data of the functional parameters after pretreatment of the kidneys with verapamil, cimetidine, cyclosporin A, quinidine or digoxin. Although some parameters were slightly changed after pretreatment with one of the inhibitory agents, no severe effects on kidney functioning could be determined. In agreement with previous investigations (Cox et al,, 1990) , the system remained stable and viable during the whole experimental period. Addition of rhodamine 123 slightly increased renal functioning as compared to control experiments, which could be concluded from a slightly decreased fractional excretion of sodium, calcium and glucose throughout the whole experimental period (P < 0.05).
Renal handling
Rhodamine 123 was cleared very rapidly from per fusate. Fig. 1 shows the perfusate concentration and corre sponding excretion rate data as a function of time. Biphasic perfusate concentration-time curves were obtained, with initially a rapid decline (50% of the amount rhodamine 123 was cleared after 35 min of perfusion), and subse quently a virtual infinite terminal phase. The urinary excre tion rate increased slowly after addition of rhodamine 123, a maximum rate was achieved after 40-50 min followed by a gradual decrease. Within the perfusate concentration range, the renal clearance was 1-4 times higher than the clearance by glomerular filtration (renal fractional clear ance or C1R/ G F > 1), indicating active secretion of rho damine 123 ( Fig. 2A) . Surprisingly, the renal clearance of rhodamine 123 (at a dose of 1.5 jxg) was not affected by the P-glycoprotein inhibitors, cyclosporin A (5 juig/ml) and digoxin (10 (ljlM ) (Fig. 2B) . However, pretreatment of the kidneys with cimetidine (10 |jlM) and quinidine (6 |xM) resulted in a significant reduction in renal rhodamine 123 clearance. Treatment with 10 or 50 |jlM verapamil also resulted in a significantly decreased renal clearance of rhodamine 123 (Fig. 2C) . None of the inhibitors had an effect on the perfusate concentration-time profiles of rho damine 123, suggesting that transport from perfusion fluid into the tubular cells was unaffected. Treatment with 50 [xM verapamil resulted in a C1R/G F < 1, suggesting that a reabsorptive mechanism is also involved in the overall renal clearance of rhodamine 123.
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Renal clearance/GFR
To further investigate renal excretion and reabsorption of rhodamine 123, preload experiments were performed. In these experiments, the perfused kidneys were exposed to 150 jxg rhodamine 123 for 60 min, after which the kidneys were connected to clean perfusion fluid. Functional param eters of the perfused kidneys in preload experiments were not different from the parameters in normal clearance experiments (data not shown). In order to determine the mechanism of reabsorption for rhodamine 123 found after pretreatment with 50 jxM verapamil, urine flow was changed after preloading the kidneys. Fig. 3 presents the curves of the perfusate rate and renal excretion rate of rhodamine 123 as a function of time, with and without pretreatment of the kidneys with 50 jjlM verapamil. Evi dently, a certain amount of rhodamine 123 is transported back from tubular cells to the perfusion fluid (upper panel), and a urinary flow change from 60 to 16 fxl/min hardly affected this transport (A versus B). Verapamil (50 |xM) significantly reduced rhodamine 123 transport back into the perfusion medium. The renal excretion rate after preloading the kidneys with rhodamine 123 decreased with the urine flow, indicating that passive back-diffusion prob ably accounts for the reabsorptive mechanism found ear lier. At a urinary flow of 16 jxl/m in, a renal excretion rate of 118 ± 18 n g /m in was found (Fig. 3, lower panel, B) , which is very similar to the renal excretion rate of rho damine 123 after addition of 150 jxg in the normal clear ance experiments (103 ± 12 ng/m in, Fig. 1 ). This sug gests that in the overall renal clearance of rhodamine 123 membrane passage from cell to tubular lumen is the ratelimiting step in secretion. Pretreatment of the perfused 
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R. Masereeuw et al. / European Journal o f Pharmacology 321 (1997) kidneys with verapamil resulted in significantly lower excretion rates, which were also similar to the rates ob tained in the normal clearance experiments in presence of 50 |xM verapamil. Rhodamine 123 excretion rates were 41 + 6 and 27 ± 6 for preload and normal clearance exper iments, respectively, which corresponded with a reduction in renal clearance of approximately 70%.
Renal accumulation
The rapid disappearance from perfusion fluid and the delayed appearance in urine of rhodamine 123, indicate that the compound is retained by the tubular cells. In Fig.  4 , the concentration of rhodamine 123 in the kidney, expressed as the amount of drug per weight of tissue, is plotted as a function of time. For every time point, the concentration was estimated by subtracting the amount in perfusate and the amount excreted in urine at time t from the total amount added to perfusate at time 0. Actual kidney tissue concentrations were determined at the end of the experiments and presented in Tables 2 and 3 . For every rhodamine 123 dose, the tissue concentration is 30-40% lower than the estimated concentration after 120 min of perfusion. Probably because of an extensive intracellular binding we were not able to recover 100% of the theoreti cally calculated concentration in kidney tissue (Fig. 4) . Furthermore, the accumulation ratios are given, which were obtained by dividing the concentration in kidney tissue by the concentration at the end of the experiment (Tables 2 and 3) , Between the doses, similar accumulation ratios were found. Treatment with cimetidine and quinidine significantly enhanced the cellular rhodamine 123 uptake.
Discussion
The kidneys used in this study showed a good renal functioning, and were stable for at least 2 h. Surprisingly, the fractional excretion (%) of sodium, calcium and glu cose decreased after addition of rhodamine 123, indicating that kidney viability increased as compared to control experiments. This is in contrast with several in vitro investigations showing that rhodamine 123 possesses a cytotoxic potential, including uncoupling of oxidative phosphorylation and mitochondrial swelling Emaus et al., 1986; Lampidis et al., 1983) . The reason that we did not find a decrease in renal function is Table 2 Effect of various drugs on the accumulation of rhodamine 123 in the isolated perfused rat kidney a a Mean data ± S.D. are presented. Measurements as described in Section 2. In the presence of b 10 jjlM verapamil, c 50 jxM verapamil, d 10 |jlM cimetidine, e 10 |xM digoxin, f 6 |jlM cyclosporin A and g 6 jjlM quinidine. h P < 0.05: significantly different from the same dose without treatment; n represents the number of perfused kidneys used.
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321 most likely a result of the low concentrations we used; perfusate concentrations were between 25 nM and 2.5 jjlM. At these concentrations other investigators also found little or no toxic effects for rhodamine 123 (Emaus et al., 1986) . However, we have no explanation for the slight increase in proximal tubular function observed in the present study. Kidney functional parameters were hardly changed due to the presence of verapamil, cimetidine, cyclosporin A, quinidine or digoxin in perfusion fluid. In contrast with the known renal effects of verapamil (Chan and Schrier, 1990) , the fractional excretion of calcium and glomerular filtra tion rate were not enhanced in the isolated perfused rat kidney, which can be explained by the fact that blood vessels are maximally dilated in this preparation.
Our clearance experiments demonstrate that the cationic drug, rhodamine 123, is efficiently secreted by the per fused kidney in a dose-dependent manner. Fig. 2 shows that the C1r / G F of the lowest dose is significantly higher than that for the highest dose (3.1 ± 0 .5 vs. 1.6 ± 0 .2 ; P < 0.01), indicating active, saturable secretion. However, it is unlikely that P-glycoprotein is involved. Cyclosporin A, a potent P-glycoprotein inhibitor, which has been shown to inhibit rhodamine 123 efflux in multidrug resistant cells (Lee et al., 1994) and in the isolated perfused rat liver (Stapf et al., 1994) , failed to reduce the renal excretion of the compound in the isolated perfused rat kidney. Further more, digoxin, a substrate for P-glycoprotein, was not able to affect rhodamine 123 transport either, Two other Pglycoprotein inhibitors, verapamil and quinidine, signifi cantly reduced renal rhodamine 123 clearance, however, this effect is probably related to the organic cation carrier of which both compounds are also known to be good inhibitors (Pritchard and Miller, 1993) . Supporting evi dence is given by cimetidine, an effective inhibitor of the organic cation carrier (Somogoyi, 1987; Boom et al., 1992) , which reduced the renal rhodamine 123 clearance by as much as 70%. It was recently speculated that cimeti dine might also be a substrate for P-glycoprotein, because in a distal tubule derived epithelial cell line (Madin-Darby canine kidney cells) transfected with human P-glyco protein an increased capacity for cimetidine transport from basolateral to luminal membrane was observed (Pan et al., 1994) . However, in the same model it was also shown that cimetidine was not able to inhibit transport of P-glyco protein substrates. Additionally, cimetidine had no effect on the P-glycoprotein-mediated biliary excretion and dis position of cyclosporin A (Hughes et al., 1995) , an in hibitor as well as a substrate for P-glycoprotein (Saeki et al., 1993) . Therefore, we believe that the inhibitory po tency of cimetidine is related to inhibition of the organic cation system, although the involvement of P-glycoprotein-mediated transport in overall renal rhodamine 123 excretion can not be ruled out completely, because both transport systems exhibit overlapping substrate specifici ties (Ford and Hait, 1990) . A recent study with daunomycin in renal proximal tubules of killifish revealed that P-glycoprotein and the organic cation system may provide parallel excretory pathways for drugs in the kidney (Miller, 1995) .
Organic cation transport in renal proximal tubules in volves entry into the tubular cell by (facilitated) diffusion, for which the potential difference over the basolateral membrane of -60 to -80 mV is the driving force (Pritchard and Miller, 1993) . Although the contribution of a nonsaturable active uptake mechanism for rhodamine 123 into proximal tubular cells can not be ruled out completely, the similar accumulation ratios at different perfusate concentrations and the lack of an effect of any of the inhibitory agents on the perfusate concentration-time curves suggest that the compound enters the cells by (facilitated) diffusion. After preloading the kidneys with a high dose of rhodamine 123, a substantial amount of the drug was transported back into the perfusion fluid, suggest ing that the basolateral organic cation carrier is bidirec tional and driven by the concentration gradient. Verapamil significantly reduced rhodamine 123 back-flux by about 50%, indicating that this transport is specific. These two properties are in agreement with the characteristics found for facilitated diffusion, as has been described for the basolateral organic cation system. The next step in proximal tubular secretion is transport into the luminal compartment. For organic cations this step is active and in exchange for protons (Pritchard and Miller, 1993) . Since neither one of the inhibitors affected the plasma concentration-time curves, active secretion may be considered to take place at the luminal membrane. An important finding in the characterization of the overall excretion of rhodamine 123 is that the rate-limiting step in secretion is transport from tubular cells into the luminal compartment. Pietruck and Ullrich (1995) showed previ ously that rhodamine 123 exhibits affinity for the renal organic cation system, but to a higher extent for the luminal carrier in comparison to the basolateral carrier. Furthermore, they also observed a net reabsorption in their in situ perfused rat kidney preparation, but in contrast to our results they suggested that reabsorption is an active mechanism. The preload experiments in our study revealed that reabsorption is a passive process.
Because perfusate clearance was initially very rapid and urinary excretion delayed, a substantial amount of rho damine 123 must be retained by the tubular cells. We were able to estimate the amount accumulated in kidney tissue accurately in the course of the experiment. The extensive accumulation found for rhodamine 123 in the isolated perfused rat kidney, with tissue-to-medium concentrations up to 360, can not be simply explained by uptake driven by the electrochemical gradient, which is the mechanism for basolateral entry of organic cations. The similar accu mulation ratios at different perfusate concentrations may signify that uptake of rhodamine 123 is not mediated by an active mechanism, which is able to transport the organic cation to levels above its electrochemical gradient. There fore, the drug is most likely subject to intracellular seques tration. In addition, the biphasic profile of the perfusate concentration-time curves suggests the existence of an intracellular compartment in the renal handling of rhodamine 123. Earlier reports showed that rhodamine 123 accumulates specifically in mitochondria Emaus et al., 1986) , probably driven by the inside negative membrane potential of these organelles ( -220 mV), Preliminary uptake experiments in isolated proximal tubular cells of the rat kidney using confocal microscopy, demonstrated that intracellular accumulation may include more than ju st m itochondrial com partm entation (Masereeuw et al., unpublished findings) . Additional organellar compartments that sequester this cationic dye may be endosomes, lysosomes and Golgi vesicles. These or ganelles are more acidic than the surrounding cytoplasm, and the inside negative pH gradient may drive organic cation uptake (Mellman et al., 1986) . A recent study on tetra-ethylammonium accumulation in rat kidney cortex endosomal vesicles showed that uptake is specific, ATPdependent, and driven by a pH-gradient (Pritchard et al., 1994) , Whether or not such a specific sequestration mecha nism is involved in rhodamine 123 accumulation remains to be determined.
Significant enhancement of rhodamine 123 accumula tion in the perfused kidney was found for cimetidine and quinidine, probably due to inhibition of the cation system at the luminal membrane. For cimetidine it has been reported that this cationic drug exhibits a higher affinity for the luminal transporter than for the basolateral system (Pietruck and Ullrich, 1995) , and possesses also a higher inhibitory potency against the luminal system (Boom et al,, 1992) . Less clear is why verapamil did not reduce the renal accumulation of rhodamine 123. An explanation may be that verapamil reduced both influx and efflux of the or ganic cation. Supporting evidence is given by the preload experiments in which verapamil was able to affect the back-flux of rhodamine 123 into perfusion medium by inhibition of the basolateral system. In summary, rhodamine 123 is actively secreted in the isolated perfused rat kidney. Transport across the luminal membrane into the tubular urine was found to be the rate-limiting step in overall excretion. Renal clearance was susceptible to inhibition by cimetidine, quinidine and vera pamil, but not to cyclosporin A and digoxin. These obser vations suggest that rhodamine 123 is predominantly se creted by the organic cation transport system in the iso lated perfused rat kidney, and that P-glycoprotein transport plays a minor role.
